

## **Suven Life Sciences Ltd to present two Scientific posters on Masupirdine at 2021 Clinical Trials in Alzheimer's Disease (CTAD) Conference, Boston, USA**

Hyderabad, India (November 8, 2021): Suven Life Sciences announced today that it will be presenting two scientific posters on Masupirdine at the 14th Annual Clinical Trials on Alzheimer's Disease (CTAD) conference to be held during 9-12, November 2021 in Boston, USA.

Suven Life Sciences completed Phase 2A proof of concept study and evaluated the efficacy, safety and tolerability of Masupirdine (SUVN-502) in 560 Alzheimer's patients with a triple combination study. Masupirdine is a promising potent, highly selective and pure 5-HT6 receptor antagonist in development as a novel approach in the symptomatic treatment of Alzheimer's Disease. Unfortunately, it did not meet the end point in efficacy but has great safety profile. Sub group analysis of the data provided good indication for agitation and aggression in Alzheimers type dementias. Those indications are being presented at CTAD as below.

LRP1: Beneficial Effects of Masupirdine on Psychosis in Patients with Alzheimer's disease, Addressing Limitations of Current Pharmacological Interventions

LRP2: Beneficial Effects of Masupirdine on Agitation in Patients with Alzheimer's disease: A Novel Non-Sedating Mechanism

### ***Disclaimer and Risk Statement:***

***Any information on Suven Intellectual Properties, Grant of Patents and Publications related to IP/Patents provided herewith is on as-is-where-is basis and all of the statements, expectations and assumptions, including expectations and assumptions, if any, contained in this update may be forward-looking that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Suven may not undertake to update any forward-looking statements that may be made from time to time.***

## **Suven Life Sciences Limited**

Registered Office: 8-2-334 | SDE Serene Chambers | 6th Floor Road No.5 | Avenue 7  
Banjara Hills | Hyderabad – 500 034 | Telangana | India | CIN: L24110TG1989PLC009713  
Tel: 91 40 2354 1142/ 3311/ 3315 Fax: 91 40 2354 1152 Email: info@suven.com website: www.suven.com